By targeting GLP-1, GIP, and glucagon receptors, retatrutide suppresses appetite, delays gastric emptying, and increases energy expenditure
For the future, we hope GLP-1- based drugs together with antithrombotic medications can be a promising field to improve prevention and management of coronary events, also in nondiabetic patients, resulting in reduced mortality in patients with CAD
Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial
However, results can vary from person to person, and it is crucial to consult with a healthcare professional before beginning any new supplement regimen